Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. GLP-1 Solution
WARNING LETTER
•GLP-1 Solution•August 31, 2025

GLP-1 Solution – FDA Warning Letter, Aug 31, 2025

Record Details

**FDA Warning Letter Summary**

**Company:** GLP-1 Solution **Location:** Berlin, Germany **Inspection Date:** August 2025 **Warning Letter Date:** September 9, 2025

**Key Violations/Issues:** The FDA reviewed GLP-1 Solution"s website and identified significant regulatory violations concerning their compounded drug products, including retatrutide, semaglutide, and tirzepatide. The main issues are:

1. **Unapproved New Drugs:** The compounded retatrutide products are classified as unapproved new drugs. They lack FDA approval, violating sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FDCA).

2. **Misbranding:** The retatrutide products are also misbranded under section 502(f)(1) of the FDCA because they lack adequate directions for use, making them unsuitable for self-diagnosis and treatment by non-medical practitioners.

3. **False or Misleading Claims:** Claims on the website regarding semaglutide and tirzepatide products are deemed false or misleading, implying equivalence to FDA-approved products, which violates sections 502(a) and 502(bb) of the FDCA.

**Regulatory Framework:** The violations fall under the FDCA, specifically sections 505(a), 502(f)(1), 301(a), and 301(d) for unapproved and misbranded drugs, and sections 502(a) and 502(bb) for false advertising.

**Required Actions:** GLP-1 Solution must cease the introduction of these unapproved and misbranded drug products into interstate commerce and correct the misleading claims on their website. Compliance with FDA regulations is mandatory to avoid further enforcement actions.

Company
GLP-1 Solution
Inspection date
August 31, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • George Tidmarsh (Director)
View Company Profile

ID · e06ab98b-77b1-4350-9179-f01f30da59d6

Violation Codes10
FD&C Act 505(a)FD&C Act 502(f)(1)FD&C Act 301(a)FD&C Act 301(d)21.U.S.C. 355(a)21 U.S.C. 352(f)(1)21 U.S.C. 331(d)FD&C Act 502(a)FD&C Act 502(b)21 U.S.C. 352(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore GLP-1 Solution
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.